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Summary
Atypical hemolytic uremic syndrome (HUS) presents
with the clinical features of hypertension, microan-
giopathic hemolytic anemia, and acute renal failure.
Both dominant and recessive modes of inheritance
have been reported. This study describes the genetic
and functional analysis of a large Bedouin kindred
with autosomal recessive HUS. The kindred consists
of several related nuclear families in which all parent
unions of affected children are consanguineous. A pre-
vious report demonstrated that a dominant form of
HUS maps to chromosome 1q and that complement
factor H (CFH), a regulatory component of the com-
plement system, lies within the region and is involved
in the dominant disorder. Early-onset and persistent
hypocomplementemia in this Bedouin kindred
prompted us to evaluate the CFH gene. Linkage anal-
ysis was performed, demonstrating linkage between
the disorder and the markers near the CFH gene. Mu-
tation analysis of the CFH coding region revealed a
single missense mutation. Functional analyses dem-
onstrate that the mutant CFH is properly expressed
and synthesized but that it is not transported normally
from the cell. This is the first study reporting that a
recessive, atypical, early-onset, and relapsing HUS is
associated with the CFH protein and that a CFH mu-
tation affects intracellular trafficking and secretion.
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Introduction
Hemolytic uremic syndrome (HUS) is a microangio-
pathic disease of various etiologies. Atypical HUS is
characterized by the absence of antecedent diarrhea, the
tendency to relapse, a positive family history, and a poor
outcome (Kaplan et al. 1975; Kaplan 1977; Kaplan and
Proesmans l987; Segal and Sinai 1995). Both autosomal
dominant (MIM 134370) (Farr et al. 1975) and recessive
(MIM 235400) (Kaplan et al. 1975; Mattoo et al. 1989)
modes of inheritance have been reported for familial
HUS. Previous studies have reported an increased inci-
dence of human-leukocyte-antigen (HLA) B40 group an-
tigens in children with typical HUS. Both low C3 levels
and hypocomplementemia have been reported (Barre et
al. 1977; Gonzalo et al. 1981; Bogdanovic et al. 1988,
1997; Pichette et al. 1994). Recently, several families
with familial HUS and low serum complement factor H
(CFH) levels were described. CFH deficiency has been
associated with an increased tendency for several dis-
eases, including systemic lupus erythematosus (Fijen et
al. 1996), pyogenic infection susceptibility (Warwicker
et al. 1998), type II membranoproliferative glomerulo-
nephritis (Jansen et al. 1995), a form of chronic collagen
type III glomerulopathy (Vogt et al. 1995; West and
McAdams 1998), and atypical familial HUS (Ohali et
al. 1998).
We recently described the clinical pathological fea-
tures and complement studies of a Bedouin kindred with
autosomal recessive HUS (Ohali et al. 1998). All patients
were members of one extended inbred Bedouin kindred
and had low C3 and hypocomplementemia during and
between relapses. Serum CFH levels were either signif-
icantly lower or absent in affected patients compared
with unaffected siblings and parents, which suggests that
a mutant form of this regulatory protein of the comple-
ment cascade could cause the disorder.
Material and Methods
Subjects
This study evaluated Bedouin-Arab patients from a
single large kindred with atypical HUS and their unaf-
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Table 1
Primers from the CFH Coding Region for Use in SSCP
CFH Primer
Name 5′ Sequence
Size
(bp) 3′ Sequence
CFHexon1 ATGGGCTATTTCTGTAGCAG 205 CATTTCCTTAATGGATTAAG
CFHexon2 CAGAAAAGGCCCTGTGGACA 182 CATATAGGAATATCATTGGT
CFHexon3 GAAGTTGTGAAGTGTTTACC 193 ACACACTTTGGTTTCTCTTT
CFHexon4 GAAATTTCATGCAAATCCCC 169 TCACATGAAGGCAACGGACG
CFHexon5 GAAAAATCATGTGATAATCC 170 ACATCTCGGAGCAGGTATCC
CFHexon6 ACCTTGAAACCTTGTGATTA 197 CATGGTACTGCTGGCGACCA
CFHexon7 CTCAGAAAATGTTATTTTCC 173 ATGCATCTGGGAGTAGGAGA
CFHexon8 CGTGTCAAAACATGTTCCAA 210 TGCACGTGGGTTGAGCTCAC
CFHexon9 AAATCTTGTGATATCCCAGT 178 AACATATGGGTAAATCAGAC
CFHexon10 GAAAGAGAATGCGAACTTCC 176 TTACATATTGGGAGGTCAGG
CFHexon11 GAGCAAGTACAATCATGTGG 185 ACAATACACACTGGTAAAGT
CFHexon12 GAGGAGAGTACCTGTGGAGA 186 ATTGCCACACACTGGGGAAG
CFHexon13 GATAAACTTAAGAAGTGCAA 174 CCATTGAGCAGTTCACTTCT
CFHexon14 CAAATACAATTATGCCCACC 179 ACACAGAGTGGTATTGACT
CFHexon15 GAAAAAATTCCATGTTCACA 182 CACTGAGGTGGAGAACTCCA
CFHexon16 GAAGGCCTTCCTTGTAAATC 181 TGCATGATGGAGGGTGAGAC
CFHexon17 AAACAGATTGTCTCAGTTTTA 175 CTGCATGTTGGCCTTCCTGT
CFHexon18 GACACCTCCTGTGTGAATCC 179 TGCATTGAGGTGGTTCCGTC
CFHexon19 GATTCTACAGGAAAATGTGG 188 AAGCATTTTGGTGGTTCTGA
CFHexon2021 CCGTGTGTAATATCCCGAGA 211 GCACAAGTTGGATACTCCAG
fected siblings and parents. Atypical HUS was defined
as a simultaneous occurrence of microangiopathic he-
molytic anemia and acute renal insufficiency that was
not preceded by either a diarrheal prodrome or an en-
teric infection caused by cytotoxin-producing microor-
ganisms. Informed consent was obtained from all family
members participating in the study.
Genotyping
DNA was prepared from whole blood by use of a
standard protocol, and the concentration was deter-
mined by spectrophotometry at optical density 260.
DNA was diluted to a final concentration of 20 ng/ml.
Single-tandem-repeat polymorphisms (STRPs) were am-
plified in an 8.4-ml PCR mixture containing 40 ng DNA;
1.25 ml PCR buffer stock (100 mM Tris-HCl pH 8.8,
500 mM KCl, 15 mM MgCl2, and 0.01% w/v gelatin);
200 mM each dATP, dCTP, dGTP, and dTTP; 2.5 pmol
each forward and reverse primer; and 0.25 U Taq poly-
merase. PCR reactions were performed under the fol-
lowing conditions: 35 cycles each at 94C for 30 s, 55C
for 30 s, and 72C for 30 s. PCR products were elec-
trophoresed on denaturing polyacrylamide (6%) gels
(containing 7.7 M urea). The gels were visualized by
silver staining. Genotyping was performed with the use
of the following markers: D1S191, D1S202, D1S2757,
D1S412, D1S408, D1S2794, D1S2840, GATA135F02,
D1S1660, D1S1175, F13B, D1S1276, D1S1647,
D1S249, and D1S245. The STRPs used in this study
were developed by the Cooperative Human Linkage
Center, Ge´ne´thon, and the University of Utah (Sheffield
et al. 1995; UtahMarker Development Group 1995; Dib
et al. 1996). Genotypes were independently scored by
two observers and were entered into a local database.
Linkage Analysis
Linkage analysis was performed on the family with
HUS, by use of the Mendel program (Lange et al. 1988),
which accommodates inbreeding loops in the family. The
disease was assumed to be transmitted in an autosomal
recessive mode with complete penetrance. Allele fre-
quencies were assumed to be equal for each marker.
SSCP Analysis
PCR of CFH primers (table 1) was performed with
40 ng genomic DNA in 20-ml PCR mixtures contain-
ing 2 ml PCR buffer stock (100 mM Tris-HCl pH 8.8,
500 mM KCl, 15 mM MgCl2, and 0.01% w/v gelatin);
200 mM each dATP, dCTP, dGTP, and dTTP; 2.5
pmol each forward and reverse primer; and 0.25 U
Taq polymerase. PCR products were electrophoresed
on nondenaturing gels (5 ml glycerol, 5 ml of 5 #
Tris-borate EDTA [TBE], 12.5 ml 37.5:1 acrylamide/
bis, and 77.5 ml ddH2O) for 3–4 h in 0.25 # TBE.
The gels were visualized by silver staining (Bassam et
al. 1991). Variants seen on the SSCP gel were se-
quenced and were compared with the control samples,
to detect any changes from the normal sequence.
DNA Sequencing
PCR products were electrophoresed on a 1% agarose
gel and were purified with use of the Quiaquick Gel
Extraction kit (Qiagen). Purified PCR product (4.5 ml)
Figure 1 Family pedigree and genotypes. Blackened symbols denote affected individuals; unblackened symbols, unaffected individuals; unblackened diamond, CVS. I–VII denote generation. The
ID numbers for each member of generations V–VII are listed below each symbol. Genotypes of both flanking and linked markers are shown below ID numbers. Note that all the affected individuals
are homozygous for the markers between flanking markers D1S408 and D1S1647. Only the markers defining the critical region are listed.
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Figure 2 Representative genotypes with marker D1S1160.
Twenty-three DNA samples from the HUS kindred were analyzed by
PCR with D1S1660. The ID numbers for each lane are shown. The
unaffected parents are individuals V-1 and V-2, V-10 and V-11, and
V-4 and V-5. Lanes labeled with an “S” represent the siblings who do
not show in the pedigree but were included in the genotyping. Two
affected individuals genotyped are VI-4 and VI-24. All affected indi-
viduals are homozygous for marker D1S1160. Similar results were
obtained with other linked STRPs (data not shown).
Table 2
Pairwise Linkage Data between HUS and Markers on Chromosome 1q32
LOD SCORE AT v =
MARKER .000 .025 .050 .100 .200 .300 .400 v Zmax
D1S408  .161 .125 .329 .343 .224 .100 .150 .368
D1S2794 .752 .716 .680 .606 .457 .306 .155 .000 .752
D1S2840 1.504 1.419 1.330 1.142 .753 .401 .144 .000 1.504
GATA135F02 2.263 2.497 2.305 1.933 1.233 .634 .221 .000 2.693
D1S2660 3.036 2.806 2.581 2.146 1.336 .656 .215 .000 3.036
D1S1175 3.383 3.152 2.925 2.483 1.648 .907 .346 .000 3.383
F13B 1.564 1.472 1.379 1.194 .831 .500 .220 .000 1.564
D1S1726 .752 .716 .680 .606 .457 .306 .155 .000 .752
D1S1647  1.774 1.223 .733 .339 .170 .068 .500 .500
was used as a template for each sequencing reaction.
Then, 1 ml 20-pmol primer and 4.5 ml terminator se-
quencing mix (Amersham) were added, for a final re-
action volume of 10 ml. Cycling conditions were per-
formed as specified by the manufacturer. The sequencing
reactions were precipitated and were resuspended in 2
ml loading buffer. The reactions were analyzed on an
ABI 377 sequencer with a 3-h run time.
Western Blot Assay
Serum CFH analysis was performed by western
blotting, as described elsewhere (Vogt et al. 1995). In
brief, serum samples (20 ml serum diluted 50-, 100-,
and 200-fold with saline) were exposed to SDS PAGE
and were transferred onto a nitrocellulose membrane.
CFH on the membrane was visualized by serial in-
cubations with specific monoantibodies, then with
second antibodies conjugated with peroxidase and
then with diaminobenzidine as substrate.
Pulse-Chase Assay
Skin-derived fibroblasts from affected individuals
and from normal control individuals were grown to
confluence, in multiwell tissue-culture plates, in Dul-
becco’s minimal essential medium (DMEM) contain-
ing 10% FCS; they were washed to remove serum and
spent medium and were cultured, for 16–24 h, either
in DMEM with 1 mg BSA/ml alone or in medium
containing BSA and various concentrations of inter-
leukin-1 and tumor necrosis factor. Biosynthetic ex-
periments were performed by incubation of the cells
for 2 h in methionine-free DMEM medium containing
[35S]-methionine (300 mCi/ml), as described elsewhere
(Pichette et al. 1994). Total protein synthesis was es-
timated from incorporation of [35S]-methionine into
trichloracetic acid–insoluble protein. Cell lysates and
extracellular medium were prepared for immunopre-
cipitation, were preabsorbed, and then were immu-
noprecipitated with formalin-fixed Staphylococcus
aureus. Immunoprecipitates were subjected to SDS-
PAGE, and gels were fixed, impregnated with auto-
fluor, dried, and exposed, at 70C, to X-ray film.
Incorporation of [35S]-methionine into the individual
immunoprecipitated proteins was determined in gel
slices, after digestion with 15% hydrogen peroxide
for 16 h at 65C and after addition of Ultima Gold
(Packard). The effect of the stimuli on protein syn-
thesis was normalized after correction of the specific
protein counts in the gel slices for total protein syn-
thesized in each sample. Newly synthesized CFH pro-
teins were detected by use of specific antibody.
Northern Blot Assay
Fibroblasts were grown to confluence in 162-cm2
flasks and were stimulated with interferon-g (100 ng/
ml) and tumor necrosis factor (10 ng/ml) 20 h prior
to RNA isolation. Approximately 108 cells were lysed,
and RNA was isolated by use of the method described
by Chirgwin et al. (1979). Total RNA (10 mg) was
denatured and was subjected to electrophoresis in a
1% agarose/formaldehyde gel. The RNA was trans-
ferred to a nylon membrane (Armesham Life Sciences)
and was processed as described by Vicra et al. (1990).
The nylon-bound mRNA was hybridized to nick-
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Figure 3 A, SSCP of exon 20 in family members with HUS. DNA samples were screened for mutations, by use of SSCP with primers
from the CFH coding region. The ID numbers for each lane are shown. A CVS was included in lane 16 (VII-4). Note the shifted bands
representing a mutation in the CFH gene. B, Partial chromatograms for the exon 20 codon sequence for affected individuals (VI-4) and for
unaffected individuals (VI-15). Note the mutation in affected individuals (CrT change).
translated [32P]-labeled DNA coding for the CFH
gene. Human b-actin probe was used as an internal
control.
Results
Clinical Evaluation
All patients were members of an extended inbred
Bedouin kindred (fig. 1). The median age at presen-
tation was 2 wk (range 1–20 wk). Of the 11 patients,
10 died. One is alive and is undergoing dialysis. The
clinical and histopathologic features of these patients
have been reported by Ohali et al. (1998). Thrombotic
microangiopathy with a predominant early arteriolar
involvement and subsequent development of ischemic
glomerular changes were found by renal biopsy. All
patients had low complement-component levels dur-
ing and between relapses. The complement deficiency
could not be normalized by repeat plasma transfu-
sions.
Genetic Mapping
DNA samples were available for 22 family mem-
bers, including 20 unaffected individuals and 2 af-
fected individuals (VI-4 and VI-24), and 1 chorionic
villus sample (CVS) (VII-4) was available. Genotyping
was performed with 15 STRP markers on chromo-
some 1q32. The two affected individuals were ho-
mozygous for the same allele, for markers across the
region flanked by D1S408 and D1S1647 (fig. 2). Ge-
notyping of the CVS indicated an affected fetus. The
CVS data were not used in the linkage analysis. Using
the Mendel program, we obtained a maximum LOD
score (Zmax) of 3.38, at recombination fraction (v) 0,
for the fully informative marker D1S1175 (table 2).
The flanking markers define a critical interval of 6
cM.
Mutation Analysis
After linkage of HUS was determined in the Bed-
ouin kindred, the candidate gene, CFH, was screened
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Figure 4 Western blot analysis of serum CFH from affected
individuals VII-2 (lanes 1–3), VI-4 (lanes 7–9), and VI-24 (lanes
10–12); from unaffected parents VI-19 (lane 4) and V-7 (lane 5); and
from sibling VII-3 (lane 6). P1 and P2 are the pools of unaffected
individuals corresponding to VII-2 and VI-4, respectively. The blot
was probed with antisera specific for CFH. Size markers are shown.
The serum dilutions are indicated below each lane.
Figure 5 The correlation between serum CFH and C3. Immu-
nodiffusion assay of serum from peripheral blood of unaffected parents
and siblings. CFH and C3 were measured with the use of monospecific
goat antibodies to human C complement. The protein counts were
expressed as a percentage of pooled normal sera. Correlation: r =
, .0.67 P ! .05
for mutations, with use of the primers listed in table
1. The entire 20-exon coding region was analyzed for
mutations by use of both SSCP and sequencing. SSCP
analysis detected a bandshift in exon 20. A single CrT
transition, resulting in a SerrLys (S1191L) change,
was identified at codon 3645 (fig. 3A and B). The
numbers used for nucleotides and amino acids were
based on a previously published sequence (Ripoche et
al. 1988). This transition was found to be a homo-
zygous change in the available affected individuals
and a heterozygous change in obligate carriers. That
this variant was not found in 96 control individuals
suggests that this is a disease-causing mutation. No
other sequence variants were identified, by DNA se-
quencing, in the complete coding region of the gene
in members of this family.
Serum CFH Analysis
A 155-kD band, which corresponded to the correct
size of the CFH protein, was detected by western blot-
ting in three affected individuals (VII-2, VI-4, and VI-
24), for whom serum was available, and in three un-
affected individuals (VI-19, V-7, and VII-13).
However, the detectable signal was much weaker in
affected individuals, when compared with that ob-
served in control subjects at multiple serum dilutions
(1:200–1:50) (fig. 4). Complement factors I and C3
were also tested. Normal factor-I levels were dem-
onstrated (data not shown). A correlation between C3
and CFH levels was observed in the asymptomatic
siblings and in the parent ( , ) (fig. 5).r = 0.67 P ! .05
CFH mRNA Analysis
To determine whether CFH deficiency is the result
of abnormal levels of mRNA, RNA from fibroblasts
was analyzed on northern blots by use of a CFH
cDNA probe. No difference in CFH mRNA levels was
detected between the control individuals and the af-
fected individuals (VII-2 and VI-4), with both basal
and stimulated conditions (Fig. 6). This result indi-
cates that the S1191L variant does not affect CFH
mRNA levels.
CFH and C3 Biosynthesis and Secretion Analysis
We next conducted pulse-chase experiments in
which intracellular and extracellular CFH and C3
protein levels were measured. Fibroblasts both from
patients (VII-2 and VI-4) and from control subjects
were grown in culture, and immunoprecipitated pro-
teins were detected from fibroblast lysates and culture
media, by use of antibodies specific to CFH and C3.
Gel slices containing the proteins were quantified. In-
tracellular CFH was properly synthesized in fibro-
blasts, both in affected individuals and in controls.
However, at the 2-h time point, the extracellular CFH
levels were significantly reduced in patients compared
with controls. The low extracellular CFH levels were
further evident after 8 h (fig. 7A). In contrast to CFH,
C3 levels in the medium were not significantly differ-
ent between affected individuals and control individ-
uals (fig. 7B). The results indicate that both CFH and
C3 can be synthesized normally in the affected fibro-
blasts; however, CFH is not secreted normally by fi-
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Figure 6 CFHmRNA: northern blot analysis of fibroblasts from
affected individuals VII-2 (lanes 1 and 2), VI-4 (lanes 3 and 4) and
from unaffected control individuals C1 (lanes 5 and 6) and C2 (lanes
7 and 8), in both the basal state (B) and the stimulated state (S). The
blot was probe with a CFH cDNA probe. An internal control probe
(C1I [complement 1 inhibitor]) was included. Size markers are not
shown.
Figure 7 CFH and C3 biosynthesis and secretion. Pulse-chase
experiments of CFH (A) and C3 (B) from skin fibroblasts from two
patients (denoted by “HUS”) (VI-4 and VII-2) and from two healthy
controls (denoted by “control”). Intracellular biosynthesis or extra-
cellular secretion rate at 0 h is denoted by gray bars; at 2 h, by un-
blackened bars; and at 8 h, by blackened bars. IC = Inside fibroblasts;
EC = in medium.
broblasts from affected individuals. In contrast, C3
secretion is normal.
Discussion
In the present study, linkage between the CFH gene
and autosomal recessive atypical HUS was demon-
strated in a large Bedouin kindred. A single missense
mutation (S1191L) was found in the CFH gene and
was shown to segregate with the disease. Northern
blot analysis indicates that affected individuals pro-
duce normal levels of mRNA. However, low levels of
serum CFH are present in affected individuals. Im-
munoprecipitation studies indicate that the CFH de-
ficiency is the result of abnormal secretion of the mu-
tant protein. Together, these findings provide strong
molecular evidence of CFH involvement in autosomal
recessive familial atypical HUS.
Recently, Warwicker et al. (1998) reported two het-
erozygous CFH mutations (R1197G and a 4-bp exon-
1 deletion) in an autosomal dominant familial HUS
pedigree and in an isolated HUS proband, respec-
tively. Low serum C3 and CFH levels were not evident
in affected individuals (Warwicker et al. 1998). In the
present study, a different point mutation (S1191L)
was found in the homozygous state, resulting in low
serum CFH in all affected individuals. Obligate het-
erozygotes for the S1191L mutation appear to be clin-
ically normal. These findings suggest a different dis-
ease mechanism for autosomal recessive and
autosomal dominant HUS. The autosomal recessive
disease seen in this study appears to result from a
deficiency in serum CFH caused by abnormal secre-
tion of the mutant protein, whereas the dominant dis-
ease may result from the presence of an abnormal
CFH protein secreted into the plasma.
CFH, a serum glycoprotein with a molecular weight
of 155 kD, is synthesized abundantly in the liver. It
is also synthesized in endothelium, macrophages,
platelets, leukocytes, and several other cell types (Sim
et al. 1993). CFH is a down-regulating protein of the
alternative pathway in the complement system. CFH
controls the alternative pathway in the complement
system by binding C3b (C3 convertase), thereby pre-
venting the formation of the C3 convertase complex
and accelerating the dissociation of Bb from the active
C3 convertase (Weiler et al. 1976). CFH is also a co-
factor for factor I (C3b inactivator) (Pangburn et al.
1977) and can distinguish between activator and non-
activator surfaces (Meri et al. 1990).
CFH is a 1,301-amino-acid peptide coded for a gene
on chromosome 1q32 (Ripoche et al. 1988). It con-
tains 20 short consensus repeats (SCRs) and is ho-
mologous to C4-binding protein (Skerka et al. 1995).
The SCR domains are thought to be small indepen-
dent-folding units, and each represents an exon in the
CFH gene. It is speculated that a mutation in CFH
may prevent proper SCR folding, resulting in abnor-
mal CFH transport. CFH has at least three C3b-bind-
ing domains (Sharma and Pangburn 1996); one of the
domains resides within the SCR 16–20. The low C3
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level and its correlation with CFH deficiency in our
study can be explained as secondary to increased con-
sumption of C3 rather than as a primary C3 defi-
ciency.
Mutations in CFH were previously reported to af-
fect protein secretion. Ault and coworkers (1997)
demonstrated two mutations in SCR9 and SCR16 that
caused abnormal CFH secretion and intracellular ca-
tabolism in chronic hypocomplementemic renal dis-
ease, with CFH deficiency. Both mutations affect con-
served cysteine residues characteristic of SCR
modules. In the present study, we described a point
mutation resulting in a SerrLys (S1191L) change. Ser-
ine is an amino acid with an uncharged polar side
chain, and its substitution by a charged lysine residue
may affect proper SCR folding and C3b binding,
thereby resulting in abnormal transportation and se-
cretion.
No therapy, including numerous transfusions of
fresh frozen plasma or plasmapheresis, proved to be
effective in our patients. The lack of response to
plasma therapy could be the result of either insuffi-
cient amounts of CFH in the plasma used for trans-
fusions or the presence of other components that ex-
acerbate the relapses. Isolated CFH replacement or a
more specific C-activation inhibition, such as the cir-
culating C receptor, may serve as alternatives to whole
plasma. Enhancement of CFH secretion could also be
considered as possible treatment.
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